An Early Phase 1 interventional study of LX107 Injection in Retinal Dystrophy, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Retinal Dystrophies with a site in China — 6 open to participants now, 9 under way, 1 of them phase 3. Retinal Dystrophies · China.
Among the 10 studies in Retinal Dystrophies with a site in China, this one is one of 3 that started in 2025, is one of 4 in phase 1, and was the 9th registered.
60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.
Browse Retinal Dystrophies studies →6 of the 10 studies in Retinal Dystrophies with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–55
Zhongmou Therapeutics · Sites in China
Healthy volunteers
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in China, United States, Australia
Ages 18–65
Frontera Therapeutics · Sites in China
Ages 8–45
Institute of Molecular and Clinical Ophthalmology Basel · Sites in China, United States, Germany and 4 more countries
Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 1
First in 2018; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 13 is below the median of 18 across 34 interventional studies indexed under Retinal Dystrophies.
Median enrollment 9 across the 7 interventional studies, 500 across the 3 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 7 most frequent:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 182 studies on the registry; 108 are open to participants now.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine has 2 studies filed under Retinal Dystrophies — fewer than ten, so there is no comparison to draw.
4 of the studies in Retinal Dystrophies with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05294978Institute of Molecular and Clinical Ophthalmology BaselEyeConic: Qualification for Cone-Optogenetics | 2026-12 |
| NCT07063030Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineA Study of LX107 Gene Therapy in AIPL1-IRD Patients | 2026-12-31 |
| NCT07085533Zhongmou TherapeuticsNatural History Study of Inherited Retinal Diseases | 2027-06-04 |
| NCT07656753Peking Union Medical College HospitalSafety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Retinal Dystrophies with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.
Inclusion Criteria:
Note: Only one eye will be designated as the "study eye" (i.e., the eye to receive treatment) at the investigator's discretion.
Exclusion Criteria:For any eye with the following conditions:
A history of intraocular surgery (e.g., vitrectomy, cataract surgery, trabeculectomy, or other filtering surgery) in the 6 months prior to the screening visit.
For any systemic conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: LX107 Injection Arm Description: * Low dose group: subretinal injection of LX107 -3×10⁹ VG/eye * Medium dose group: subretinal injection of LX107- 1×10¹⁰ VG/eye * High dose group: subretinal injection of LX107 -3×10¹⁰ VG/eye
Genetic: LX107 Injection
Subjects will receive subretinal injection of LX107 on Day 0.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Incidence of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) following LX107 subretinal injection
Time frame: 6 Months
Changes in Functional Magnetic Resonance Imaging (fMRI) Results
Time frame: 6 months、12 months
Mean Change from Baseline in Multi-luminance Mobility Test (MLMT)
Assess the subject's mobility ability under different light intensities using MLMT, and compare the mean changes from baseline at 180 and 365 days after treatment to reflect improvements in visual function.
Time frame: 6 months、12 months
Mean Change from Baseline in Full-Field Sensitivity Threshold (FST)
Measure the subject's light perception ability using FST, and compare the mean changes from baseline at 180 and 365 days after treatment to evaluate improvements in visual sensitivity.
Time frame: 6 months、12 months
Mean Change from Baseline in Visual Acuity (VA)
Measure VA using ETDRS and BRVT charts, with LogMAR score as the indicator, and compare the mean changes from baseline at 180 and 365 days after treatment to assess visual acuity improvement.
Time frame: 6 months、12 months
Mean Change from Baseline in Visual Fields
Use Goldmann perimeter (dynamic visual field) and Humphrey perimeter (static visual field) to compare the mean changes from baseline at 180 and 365 days after treatment, evaluating improvements in visual field range and sensitivity.
Time frame: 6 months、12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine →